摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-乙基-4-氟苄胺 | 162401-03-8

中文名称
N-乙基-4-氟苄胺
中文别名
——
英文名称
N-(4-fluorobenzyl)ethanamine
英文别名
N-Ethyl-4-fluorobenzylamine;N-[(4-fluorophenyl)methyl]ethanamine
N-乙基-4-氟苄胺化学式
CAS
162401-03-8
化学式
C9H12FN
mdl
MFCD04537942
分子量
153.199
InChiKey
CURFQQZYGVCIGJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    56-58 °C(Press: 3 Torr)
  • 密度:
    1.009±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险等级:
    8
  • 海关编码:
    2921499090
  • 包装等级:
    III
  • 危险类别:
    8
  • 危险性防范说明:
    P280,P305+P351+P338,P310
  • 危险品运输编号:
    2735
  • 危险性描述:
    H314

SDS

SDS:d5bd7c8e6a49c5bfc8c0f3617cb6631a
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: N-Ethyl-4-fluorobenzylamine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: N-Ethyl-4-fluorobenzylamine
CAS number: 162401-03-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H12FN
Molecular weight: 153.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

反应信息

  • 作为反应物:
    描述:
    N-乙基-4-氟苄胺盐酸potassium carbonate盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺 、 potassium iodide 作用下, 以 二氯甲烷乙酸乙酯乙腈 为溶剂, 反应 68.0h, 生成 1-acetyl-N-(3-chlorophenyl)-N-(3-(4-(ethyl(4-fluorobenzyl)carbamoyl)piperidin-1-yl)propyl)piperidine-4-carboxamide
    参考文献:
    名称:
    Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors
    摘要:
    Based on a putative 'Y shape' pharmacophore model of CCR5 inhibitors, a series of novel piperidine-4-carboxamide derivatives were designed and synthesized using a group-reverse strategy. Among synthesized target compounds, 16g (IC50 = 25.73 nM) and 16i (IC50 = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC50 = 25.43 nM) in calcium mobilization assay. Selected compounds were further tested for their antiviral activity in HIV-1 single cycle assay. Two compounds, 16g and 16i, displayed antiviral activity with IC50 values of 73.01 nM and 94.10 nM, respectively. Additionally, the pharmacokinetic properties and inhibitory potency against hERG of 16g were evaluated, providing a foundation for ongoing optimization. (C) 2013 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2013.11.013
  • 作为产物:
    描述:
    Ethyl-[1-(4-fluoro-phenyl)-meth-(E)-ylidene]-amine 在 sodium tetrahydroborate 作用下, 生成 N-乙基-4-氟苄胺
    参考文献:
    名称:
    三种新型Cd(II)二硫代氨基甲酸酯配合物:合成,结构多样性和荧光性质
    摘要:
    具有分子式[Cd(KL)2 ],(KL1 = C 15 H 13 N 1 F 1 S 2)的三种新的均硫的二硫代氨基甲酸镉(II)配合物(1);(L 2 = C 13 H 11 N 1 F 1 S 2)(2);( N)=1。(L3 = C 11 H 14 N 1 O 1 S 2)(3),已经通过元素分析,光谱法(IR,1 H和13CNMR和UV-Vis)。单晶X射线研究证实,配合物1在正交晶体中具有空间群P na21并保持二聚体结构结晶。在这种复杂的Cd 2+中,金属中心周围的八面体几何形状畸变,形成1D配位聚合物结构。配合物2和3的二聚体形式在空间群为P-1的三斜晶格中结晶。
    DOI:
    10.1007/s13738-020-01965-4
点击查看最新优质反应信息

文献信息

  • Deoxygenative hydroboration of primary, secondary, and tertiary amides: Catalyst‐free synthesis of various substituted amines
    作者:Jaeeun Yi、Hyun Tae Kim、Ashok Kumar Jaladi、Duk Keun An
    DOI:10.1002/bkcs.12438
    日期:2022.1
    less reactive functional groups under catalyst-free conditions is an interesting aspect and requires a typical protocol. Herein, we report the synthesis of various primary, secondary, and tertiary amines through hydroboration of amides using pinacolborane under catalyst-free and solvent-free conditions. The deoxygenative hydroboration of primary and secondary amides proceeded with excellent conversions
    在无催化剂条件下相对较少反应性官能团的转化是一个有趣的方面,需要一个典型的协议。在此,我们报告了在无催化剂和无溶剂条件下,使用频哪醇硼烷对酰胺进行硼氢化合成各种伯胺、仲胺和叔胺。伯酰胺和仲酰胺的脱氧硼氢化反应以优异的转化率进行。在无催化剂条件下,反应性相对较低的叔酰胺也以中等收率转化为相应的N,N-二胺,尽管作为次要产物获得了醇。
  • MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE
    申请人:Durand-Reville Thomas
    公开号:US20110021513A1
    公开(公告)日:2011-01-27
    The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase.
    本发明涉及IRAK激酶的调节剂,并提供包含这些调节剂的组合物,以及利用这些调节剂治疗由IRAK激酶介导或相关的疾病或病症的方法。
  • HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
    申请人:GiraFpharma LLC
    公开号:US20190023666A1
    公开(公告)日:2019-01-24
    Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    提供了氨基吡嗪化合物作为腺苷受体的调节剂。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂,并且可能在肿瘤学中发挥特定作用。
  • [EN] ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE<br/>[FR] DERIVES DE L'ACIDE BENZOIQUE ORTHO-SUBSTITUES DESTINES AU TRAITEMENT DE L'INSULINORESISTANCE
    申请人:ASTRAZENECA AB
    公开号:WO2004000294A1
    公开(公告)日:2003-12-31
    The present invention provides a compound of formula (I), wherein n is 0, 1 or 2; R1 represents halo, a C1-4alkyl group which is optionally substituted by one or more fluoro, a C1-4alkoxy group which is optionally substituted by one or more fluoro and wherein when n is 2 the substituents R1 may be the same or different; R2 represents an unbranched C2-7alkyl group; R3 represents H or OCH3; and W represents O or S and pharmaceutically acceptable salts and prodrugs thereof, to processes for preparing such compounds, to their utility in treating clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    本发明提供了一种式(I)化合物,其中n为0、1或2;R1代表卤素、可被一个或多个氟取代的C1-4烷基、可被一个或多个氟取代的C1-4烷氧基,且当n为2时,取代基R1可以相同或不同;R2代表直链C2-7烷基;R3代表H或OCH3;W代表O或S及其药学上可接受的盐和前药,以及制备此类化合物的方法,它们在治疗与胰岛素抵抗相关的临床条件中的用途,其治疗方法以及含有它们的药物组合物。
  • BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    申请人:Katayama Seiji
    公开号:US20130116227A1
    公开(公告)日:2013-05-09
    Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R 1 is a substitutable aminosulfonyl group, etc.; R 2 is a hydrogen atom, etc.; R 3 is a hydrogen atom, etc.; R 4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C 1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R 5a , R 5b and R 5c are each independently hydrogen atoms, etc.; R 6 is a halogen atom, a cyano group, etc.; R 7 and R 8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.)
    揭示了一种表示为公式(1)的新型联苯酰胺衍生物,具有与醛固酮受体的亲和力;还揭示了其药用可接受的盐。(在该公式中,A是由公式(a)表示的任何基团之一;L是—CONH—等;R1是可替代的氨基磺酰基等;R2是氢原子等;R3是氢原子等;R4是氢原子、卤原子、羟基、可替代的氨基基团、可替代的C1-6烷氧基、可替代的4-到7-成员环氨基基团等;R5a、R5b和R5c各自独立地是氢原子等;R6是卤原子、氰基等;R7和R8各自独立地是氢原子等;m是整数,例如0。)
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐